Clindamycin Hydrochloride 300 mg Capsule, 12-count
Other active recalls for Clindamycin Hydrochloride (different manufacturers) — 1 · tap to view
🆔 Identity & classification
Where does this data come from?
🏷️ RxNorm drug class
This medicine belongs to the Lincosamide Antibacterial class.
Where does this data come from?
🏭 Manufacturer & labeler
Where does this data come from?
🩺 Clinical
- Clindamycin is used for serious bacterial infections — things like deep skin infections, lung abscesses, pelvic infections, and abdominal infections. It's often chosen when penicil...
- What kinds of infections is clindamycin actually used for?
- You don't have to eat with it — food doesn't meaningfully change how it's absorbed. But the most important thing is to take each capsule with a full, large glass of water, and stay...
- Do I need to take clindamycin with food?
Patient education
Supplement & herbal interactions
Clindamycin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.1397 | $1.68 / 12 capsules |
Where does this data come from?
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Clindamycin Hydrochloride 300 mg 00904-7194-61 | Major | 100 capsules | $0.168 | AB | Availability likely | — |
| Clindamycin Hydrochloride 300 mg 42571-0252-01 | Micro | 100 capsules | $0.168 | AB | Availability likely | — |
| Clindamycin Hydrochloride 300 mg 50268-0185-15 | AvPAK | 50 capsules | $0.168 | AB | Availability likely | — |
| Clindamycin Hydrochloride 300 mg 62135-0766-01 | Chartwell | 100 capsules | $0.168 | AB | Availability likely | — |
| Clindamycin hydrochloride 300 mg 63304-0693-01 | Sun | 100 capsules | $0.168 | AB | Availability likely | — |
| Clindamycin Hydrochloride 300 mg 65862-0186-01 | Aurobindo | 100 capsules | $0.168 | AB | Availability likely | — |
| Clindamycin Hydrochloride 300 mg 68084-0244-01 | American | 100 capsules | $0.168 | AB | Availability likely | — |
| Clindamycin Hydrochloride 300 mg 68462-0144-01 | GLENMARK | 100 capsules | $0.168 | AB | Availability likely | — |
| clindamycin hydrochloride 300 mg 59762-5010-01 | Mylan | 16 capsules | $0.176 | AB | Discontinued | — |
| Cleocin Hydrochloride 300 mg 00009-0395-14 | Pharmacia | 100 capsules | — | AB | FDA listed | — |
| Clindamycin hydrochloride 300 mg 50090-0967-00 | A-S | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 50090-3907-00 | A-S | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 50090-4575-00 | A-S | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 50090-7354-00 | A-S | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 50090-7659-00 | A-S | 28 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 50090-7669-00 | A-S | 28 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 51655-0317-51 | Northwind | 40 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 55700-0761-21 | Quality | 21 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 60760-0827-10 | St. | 10 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 63187-0127-20 | Proficient | 20 capsules | — | AB | FDA listed | — |
| Clindamycin hydrochloride 300 mg 63187-0141-20 | Proficient | 20 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 67046-2073-03 | Coupler | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 67296-0940-02 | Redpharm | 28 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 67296-1749-03 | RedPharm | 40 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 67296-2149-01 | Redpharm | 21 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 68071-2346-09 | NuCare | 9 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 68071-3577-01 | NuCare | 14 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 68071-3983-09 | NuCare | 9 capsules | — | AB | FDA listed | — |
| Clindamycin hydrochloride 300 mg 68071-4257-01 | NuCare | 14 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 68071-5174-02 | NuCare | 20 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 68788-8685-01 | Preferred | 14 capsules | — | AB | FDA listed | — |
| clindamycin hydrochloride 300 mg 69238-2121-03 | Amneal | 10 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 70518-2153-00 | REMEDYREPACK | 30 capsules | — | AB | Discontinued | — |
| Clindamycin Hydrochloride 300 mg 70518-3772-00 | REMEDYREPACK | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 71205-0444-20 | Proficient | 20 capsules | — | AB | FDA listed | — |
| Clindamycin hydrochloride 300 mg 71335-0320-00 | Bryant | 16 capsules | — | AB | Discontinued | — |
| Clindamycin Hydrochloride 300 mg 71335-1412-00 | Bryant | 16 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 71335-2432-00 | Bryant | 16 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 71335-2677-01 | Bryant | 10 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 72189-0189-30 | DIRECT | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 72789-0167-09 | PD-Rx | 9 capsules | — | AB | FDA listed | — |
| Clindamycin hydrochloride 300 mg 72789-0207-09 | PD-Rx | 9 capsules | — | AB | FDA listed | — |
| Clindamycin hydrochloride 300 mg 76420-0202-12 | Asclemed | 12 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 76420-0614-01 | Asclemed | 100 capsules | — | AB | FDA listed | — |
| Clindamycin HCL 300 mg 80425-0103-01 | Advanced | 30 capsules | — | AB | FDA listed | — |
| Clindamycin HCL 300 mg 80425-0145-01 | Advanced | 30 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 80425-0416-01 | Advanced | 21 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 82804-0278-21 | Proficient | 21 capsules | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mg 83939-0019-01 | VERITYRX, | 1 capsule | — | AB | FDA listed | — |
| Clindamycin Hydrochloride 300 mgthis 85766-0028-12 | Sportpharm | 12 capsules | — | AB | FDA listed | — |
| Clindamycin hydrochloride 300 mg 85534-0088-00 | HAWAII | 8 capsules | — | AB | FDA listed | — |
Where does this data come from?
⏳ Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
🔬 Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 85766-0028-01 | 100 CAPSULE in 1 BOTTLE (85766-028-01) | 2025-08-07 | Active |
| 85766-0028-12 You're viewing this | 12 CAPSULE in 1 BOTTLE (85766-028-12) | 2025-08-07 | Active |
| 85766-0028-16 | 16 CAPSULE in 1 BOTTLE (85766-028-16) | 2025-08-07 | Active |
| 85766-0028-20 | 20 CAPSULE in 1 BOTTLE (85766-028-20) | 2025-08-07 | Active |
| 85766-0028-30 | 30 CAPSULE in 1 BOTTLE (85766-028-30) | 2025-08-07 | Active |
| 85766-0028-60 | 60 CAPSULE in 1 BOTTLE (85766-028-60) | 2025-08-07 | Active |
| 85766-0028-90 | 90 CAPSULE in 1 BOTTLE (85766-028-90) | 2025-08-07 | Active |
You're viewing the smallest of 7 pack sizes for this product.
Pack size FAQ
What quantity is in NDC 85766-0028-12?
What is the difference between NDC 85766-0028-12 and NDC 85766-0028-16?
What NDC number is used to bill for this package of Clindamycin Hydrochloride 300 mg Capsule?
🧭 About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
Questions about this listing
Why is there no price listed?
Is the NDC printed on the package the same as the 11-digit billing NDC?
What do the three segments of this NDC mean?
Is this package still being marketed?
Does this product come in other package sizes?
Who lists this product with the FDA?
Do I need a prescription for this product?
Where does this data come from?
📄 Full prescribing information FDA SPL
🚨 Boxed Warning ▾
WARNING Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin hydrochloride and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile. Because clindamycin hydrochloride therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section.
It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections. C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C . difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate.
Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra- abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection.
Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections.
Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION If significant diarrhea occurs during therapy, this antibacterial drug should be discontinued (see BOXED WARNING ). Administer clindamycin hydrochloride capsules with a full glass of water (6 to 8 ounces, approximately 200 to 250 mL) and at least 30 minutes before lying down to reduce the potential for esophageal irritation (See ADVERSE REACTIONS ). Adults : Serious infections – 150 to 300 mg every 6 hours.
More severe infections – 300 to 450 mg every 6 hours. Pediatric Patients (who are able to swallow capsules): Serious infections – 8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses. More severe infections – 16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses.
Clindamycin should be dosed based on total body weight regardless of obesity. Clindamycin hydrochloride capsules are not suitable for pediatric patients who are unable to swallow them whole. The capsules do not provide exact mg/kg doses therefore it may be necessary to use the clindamycin palmitate oral solution in some cases.
Serious infections due to anaerobic bacteria are usually treated with CLEOCIN PHOSPHATE ® Sterile Solution. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with clindamycin hydrochloride capsules. In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.
⛔ Contraindications ▾
CONTRAINDICATIONS Clindamycin hydrochloride capsules are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
⚠️ Warnings ▾
WARNINGS See BOXED WARNING Clostridioides difficile- Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin hydrochloride, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C. difficile . C. difficile produces toxins A and B, which contribute to the development of CDAD.
Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated. Anaphylactic and Severe Hypersensitivity Reactions Anaphylactic shock and anaphylactic reactions have been reported (see ADVERSE REACTIONS ).
Severe hypersensitivity reactions, including severe skin reactions such as toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS), some with fatal outcome, have been reported (see ADVERSE REACTIONS ). In case of such an anaphylactic or severe hypersensitivity reaction, discontinue treatment permanently and institute appropriate therapy. A careful inquiry should be made concerning previous sensitivities to drugs and other allergens.
Nephrotoxicity Clindamycin is potentially nephrotoxic and cases with acute kidney injury have been reported. Consider monitoring of renal function particularly in patients with pre-existing renal dysfunction or those taking concomitant nephrotoxic drugs. In case of acute kidney injury, discontinue clindamycin hydrochloride when no other etiology is identified.
Usage in Meningitis – Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following reactions have been reported with the use of clindamycin. Infections and Infestations: Clostridioides difficile colitis Gastrointestinal: Abdominal pain, pseudomembranous colitis, nausea, vomiting, and diarrhea (see BOXED WARNING ). The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS ).
Esophagitis and esophageal ulcer have been reported, particularly when taken in a lying position or with a small amount of water. An unpleasant or metallic taste has been reported after oral administration. Hypersensitivity Reactions: Generalized mild to moderate morbilliform-like (maculopapular) skin rashes are the most frequently reported adverse reactions.
Vesiculobullous rashes, as well as urticaria, have been observed during drug therapy. Severe skin reactions such as Toxic Epidermal Necrolysis, some with fatal outcome, have been reported (see WARNINGS ). Cases of Acute Generalized Exanthematous Pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, anaphylactic shock, anaphylactic reaction and hypersensitivity have also been reported.
Skin and Mucous Membranes: Pruritus, vaginitis, angioedema and rare instances of exfoliative dermatitis have been reported (see Hypersensitivity Reactions ). Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy. Renal: Acute kidney injury (see WARNINGS ).
Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing.
Immune System: Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported. Musculoskeletal: Cases of polyarthritis have been reported. To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
🔄 Drug Interactions ▾
Drug Interactions Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents. Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin.
Therefore, inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.
In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4.
🤰 Pregnancy ▾
Pregnancy: Teratogenic effects In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities. Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.
Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed. Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (3.2 and 1.6 times the highest recommended adult human dose based on mg/m 2 , respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (1.3 and 0.7 times the highest recommended adult human dose based on mg/m 2 , respectively) revealed no evidence of teratogenicity.
🧒 Pediatric Use ▾
Pediatric Use When clindamycin hydrochloride is administered to the pediatric population (birth to 16 years), appropriate monitoring of organ system functions is desirable.
🧓 Geriatric Use ▾
Geriatric Use Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. However, other reported clinical experience indicates that antibiotic-associated colitis and diarrhea (due to Clostridioides difficile ) seen in association with most antibiotics occur more frequently in the elderly (>60 years) and may be more severe. These patients should be carefully monitored for the development of diarrhea.
Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration.
🆘 Overdosage ▾
OVERDOSAGE Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg. In the mice, convulsions and depression were observed. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Human Pharmacology Absorption Pharmacokinetic studies with a 150 mg oral dose of clindamycin hydrochloride in 24 normal adult volunteers showed that clindamycin was rapidly absorbed after oral administration. An average peak serum concentration of 2.50 mcg/mL was reached in 45 minutes; serum concentrations averaged 1.51 mcg/mL at 3 hours and 0.70 mcg/mL at 6 hours. Absorption of an oral dose is virtually complete (90%), and the concomitant administration of food does not appreciably modify the serum concentrations; serum concentrations have been uniform and predictable from person to person and dose to dose.
Pharmacokinetic studies following multiple doses of clindamycin hydrochloride for up to 14 days show no evidence of accumulation or altered metabolism of drug. Doses of up to 2 grams of clindamycin per day for 14 days have been well tolerated by healthy volunteers, except that the incidence of gastrointestinal side effects is greater with the higher doses. Distribution Concentrations of clindamycin in the serum increased linearly with increased dose.
Serum concentrations exceed the MIC (minimum inhibitory concentration) for most indicated organisms for at least six hours following administration of the usually recommended doses. Clindamycin is widely distributed in body fluids and tissues (including bones). No significant concentrations of clindamycin are attained in the cerebrospinal fluid, even in the presence of inflamed meninges.
Metabolism In vitro studies in human liver and intestinal microsomes indicated that clindamycin is predominantly metabolized by Cytochrome P450 3A4 (CYP3A4), with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N- desmethylclindamycin. Excretion The average biological half-life is 2.4 hours. Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites.
Specific Populations Patients with Renal/Hepatic Impairment The elimination half-life of clindamycin is increased slightly in patients with markedly reduced renal or hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Dosage schedules do not need to be modified in patients with renal disease.
Geriatric Patients Pharmacokinetic studies in elderly volunteers (61 to 79 years) and younger adults (18 to 39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate. After oral administration of clindamycin hydrochloride, the average elimination half-life is increased to approximately 4 hours (range 3.4 to 5.1 h) in the elderly compared to 3.2 hours (range 2.1 to 4.2 h) in younger adults.
The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function 1 . Obese Pediatric Patients Aged 2 to Less than 18 Years and Obese Adults Aged 18 to 20 Years An analysis of pharmacokinetic data in obese pediatric patients aged 2 to less than 18 years and obese adults aged 18 to 20 years demonstrated that clindamycin clearance and volume of distribution, normalized by total body weight, are comparable regardless of obesity.
Microbiology Mechanism of Action Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic. Resistance Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA.
Cross-resistance between clindamycin and lincomycin is complete. Because the binding sites for these antibacterial drugs overlap, cross-resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin…
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Clindamycin Hydrochloride Capsules, USP are available in the following strengths, colors and sizes: Clindamycin Hydrochloride Capsules, USP 300 mg are size ‘0’ hard gelatin capsules with a light blue opaque cap and a light blue opaque body, imprinted with “G” on the cap and “144” on the body with black ink and filled with white to off-white powder. They are supplied as follows: Bottles of 12 Capsules, NDC 85766-028-12 (repackaged from NDC NDC 68462-144-XX) Bottles of 16 Capsules, NDC 85766-028-16 (repackaged from NDC NDC 68462-144-XX) Bottles of 20 Capsules, NDC 85766-028-20 (repackaged from NDC NDC 68462-144-XX) Bottles of 30 Capsules, NDC 85766-028-30 (repackaged from NDC NDC 68462-144-XX) Bottles of 60 Capsules, NDC 85766-028-60 (repackaged from NDC NDC 68462-144-XX) Bottles of 90 Capsules, NDC 85766-028-90 (repackaged from NDC NDC 68462-144-XX) Bottles of 100 Capsules, NDC 85766-028-01 (relabeled from NDC NDC 68462-144-01) Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].
Bottles: Preserve in tight containers. Rx only
📋 Description ▾
DESCRIPTION Clindamycin hydrochloride, USP is the hydrated hydrochloride salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin. Clindamycin Hydrochloride Capsules, USP contain clindamycin hydrochloride, USP equivalent to 300 mg of clindamycin.
Inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate and talc. The capsule shells contain FD&C blue no. 1, gelatin, and titanium dioxide.
The black imprinting ink contains black iron oxide, potassium hydroxide, propylene glycol and shellac. The structural formula is represented below: The chemical name for clindamycin hydrochloride is Methyl 7-chloro-6,7,8-trideoxy-6- (1-methyl- trans -4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L- threo -α-D- galacto -octopyranoside monohydrochloride. FDA approved dissolution test specifications differ from USP.
Structure.jpg
💬 Information for Patients ▾
Information for Patients Patients should be counseled that antibacterial drugs, including clindamycin hydrochloride capsules, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When clindamycin hydrochloride capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.
Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by clindamycin hydrochloride capsules or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic.
If this occurs, patients should contact their physician as soon as possible. Advise patients that due to the risk of esophagitis and esophageal ulcer, it is important to adhere to the administration guidance for clindamycin hydrochloride capsules (see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS ).